Achieved Health Canada Special Access Program approval to provide psilocybin-assisted therapy for depression in Ontario Completed more than 6,000 treatments to date; expanded clinic footprint increasing capacity and greater access to network of mental health specialists Reported positive preliminary results from the first Health Canada Approved, Phase II, randomized clinical trial of multi-dose…


Previous articleatai Life Sciences to Announce Second Quarter 2022 Financial Results and Business Update
Next articleCOMPASS Pathways to participate in upcoming BTIG Biotechnology Conference and Canaccord Annual Growth Conference